ZymoGenetics alters drug development agreements

By Associated Press
September 3, 2008 | Comments (0)

Recs

0

Panic 2008... Profit 2009!

Fool -- Now's the time to invest! David and Tom Gardner's new book reveals their strategy for million dollar wealth.

Biotechnology drugmaker ZymoGenetics said Wednesday it restructured its agreement with partner Merck Serono for the development of treatment for autoimmune diseases.

ZymoGenetics said it will no longer fund the development of atacicept, which is being studied as a treatment for lupus, multiple sclerosis and rheumatoid arthritis. Under the new agreement, Merck Serono will be responsible for developing the treatment, and ZymoGenetics will receive royalties from its sale. Merck Serono is a division of Darmstadt, Germany-based Merck KGaA.

The companies said they also revised research agreements for two other experimental drugs to pare costs. ZymoGenetics will now control the development of IL-31 mAb, and Merck Serono will be responsible for developing IL-17RC. Both drugs are being studied as potential treatments for inflammatory diseases.

Shares of ZymoGenetics Inc. rose 11 cents to $8.54.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 719598, ~/articles/articlehandler.aspx, 1/8/2009 1:55:45 AM

Sign up for FREE Motley Fool site access to keep reading:

“ZymoGenetics alters drug development agreements”

Signing up allows you to comment on articles and on the discussion boards.

It's completely FREE and will take only 10 seconds.

Privacy / Legal Information

We will use your email address only to keep you informed about updates to our web site and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement

.

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Delicious
Print Digg RSS

What Fools Are Saying

Most Recent

Most Recommended

Jan 7 at 4:08 PM

Market Summary

DJIA 8,769.70 -245.40 -2.72%
S&P 500 906.65 -28.05 -3.00%
NASD 1,599.06 -53.32 -3.23%
Sponsored by:

Related Tickers

ZymoGenetics, Inc.

CAPS Rating 2/5 Stars

$3.17

-0.03 (-0.94%)

Outperform103

Underperform26

Rate This Stock

All stories about ZGEN